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Abstract
PURPOSE: The factors preventing the translation of preclinical findings supporting the clinical development mTOR-
targeted therapy in pancreatic cancer therapy remain undetermined. Stromal cell–derived factor 1α (SDF-1α)–CXCR4 sig-
naling was examined as a representative microenvironmental factor able to promote mTOR-targeted therapy resistance
in pancreatic cancer. EXPERIMENTAL DESIGN: Primary pancreas explant xenografts and in vitro experiments were used
to perform pharmacodynamic analyses of SDF-1α–CXCR4 regulation of the mTOR pathway. Combinatorial effects of
CXCR4, EGFR, and mTOR pharmacologic inhibition were evaluated in temsirolimus-resistant and -sensitive xeno-
grafts. Intratumoral gene and protein expressions of mTOR pathway effectors cyclin D1, c-Myc, and VEGF were evalu-
ated.RESULTS:Baseline intratumoral SDF-1αgeneexpressioncorrelatedwith temsirolimus resistance in explantmodels.
SDF-1α stimulation of pancreatic cells resulted in CXCR4-mediated PI3-kinase–dependent S6-RP phosphorylation
(pS6-RP) on exposure to temsirolimus. Combinatorial therapy with AMD3465 (CXCR4 small-molecule inhibitor) and
temsirolimus resulted in effective tumor growth inhibition to overcome temsirolimus resistance. In contrast, SDF-1α
exposure induced a temsirolimus-resistant phenotype in temsirolimus-sensitive explants. AMD3465 inhibited CXCR4-
mediated intratumoral S6-RP phosphorylation and cyclin D and c-myc gene expression. Next, CXCR4 promoted intra-
tumoral EGFR expression in association with temsirolimus resistance. Treatment with AMD3465, temsirolimus- and
erlotinib-mediated tumor growth inhibition to overcome temsirolimus resistance in the explant model. Lastly, SDF-1α–
CXCR4 signaling increased intratumoral VEGF gene and protein expression. CONCLUSIONS: SDF-1α–CXCR4 signaling
represents amicroenvironmental factor that canmaintainmTORpathway fidelity to promote resistance tomTOR-targeted
therapy in pancreatic cancer by a variety of mechanisms such as recruitment of EGFR signaling and angiogenesis.
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Introduction
Pancreatic adenocarcinoma remains a devastating disease, with a pre-
dicted 5-year survival at the time of diagnosis of only 4% [1]. Onco-
genesis occurs through the development of premalignant pancreatic
intraepithelial neoplasms (PanIN) that are associated with the sequen-
tial acquisition of specific genetic abnormalities [2,3]. The acquisition
of K-ras–activating mutations is a key initiator in pancreatic tumori-
genesis. K-ras-mediated mTOR (mammalian target of rapamycin)
pathway activation is an important component of pancreatic tumor
initiation and K-ras–independent maintenance of oncogenesis [4–8].
mTOR integrates signals generated by nutrients and growth factors
through the PI3-kinase/Akt pathway and regulates key cellular processes
[9]. The mTOR inhibitors, rapamycin and temsirolimus, negatively
affect pancreatic cancer cell proliferation [10–12]. Consistent with these
in vitro observations, temsirolimus and gemcitabine, in combination,
demonstrate significant antitumor effects in preclinical xenograft models
[12]. The expression of vascular endothelial cell growth factor (VEGF)
has been associated with growth-inhibitory effects of mTOR inhibitors.
However, when these data are extrapolated to the clinical setting, mTOR
inhibitors unfortunately demonstrate limited clinical activity against
pancreatic cancer [13–15]. The surprising lack of clinical benefit in these
studies suggests that the presence of alternative survival factors abrogates
the effect of inhibiting mTOR alone. Several stromal elements have
been implicated in cancer cell survival, including the chemokine stromal
cell–derived factor 1α (SDF-1α)/CXCR4 ligand-receptor pair.
The chemokine stromal–derived factor 1α (SDF-1α, CXCL12) and
its receptor CXCR4were initially demonstrated to be critical for hemato-
poiesis and neurogenesis [16]. CXCR7 has also been demonstrated to
function as an SDF-1α receptor [17]. Subsequently, SDF-1α has been
shown to enhance the metastatic potential of cancer cells through pref-
erential activation of the Akt andmitogen-activated protein kinase path-
ways in a diverse array of histologic subtypes [18–23]. Importantly,
SDF-1α expression has been associated with a poor prognosis in patients
with resected early-stage pancreatic cancer [24]. Furthermore, whereas
the role of SDF-1α and its ligand CXCR4 in pancreatic cancer remains
to be defined, evaluation of a series of PanIN samples has demonstrated
an increased frequency of CXCR4 expression associated with PanIN
progression [25]. In addition, CXCR4 expression is associated with
poor survival in patients with advanced disease states [26]. These clinical
observations underscore the potential importance of SDF-1α and
CXCR4 in pancreatic cancer development and progression.
Pancreatic cancer represents a relative hypoxic tumor in which the
intratumoral vasculature is compressed by the tumor-associated stro-
mal components. Under hypoxic conditions, mTOR signaling can
promote VEGF transcription in a hypoxia-inducible factor 1α (HIF-
1α)–dependent manner. Both SDF-1α and CXCR4 are HIF-1α target
genes that are transcribed in response to hypoxia. Hypoxic damage to
the liver results in the recruitment of endothelial precursor cells to
promote intrahepatic angiogenesis in response to SDF-1α secretion.
SDF-1α–CXCR4 ligand-receptor binding positively regulates VEGF
expression under hypoxic conditions, thus providing direct evidence
of the interplay between SDF-1α–CXCR4 signaling and mTOR-
dependent VEGF regulation. In this article, we present data supporting
the hypothesis that CXCR4 propagates secondary intracellular signals
that bypass the molecular blockade caused by mTOR inhibitors to pro-
mote therapeutic resistance mTOR-targeted therapy. Furthermore,
SDF-1α–CXCR4 regulation of VEGF may serve as a potential down
mechanism by which persistent mTOR activation induced by CXCR4
signaling promotes resistance to rapalogs. In summary, these data pro-
vide a paradigm by which extracellular components may directly regu-
late the antiproliferative characteristics of mTOR-targeted agents as a
direct function of microenvironmental cues.
Materials and Methods
Drugs
Temsirolimus (Pfizer, New York, NY) was dissolved in a propri-
etary diluent and administered daily by intraperitoneal injection at a
dose of 20 mg/kg. AMD3465 is a CXCR4 small-molecule inhibitor
that was provided by Genzyme Corporation (Cambridge, MA).
AMD3465 was dissolved in phosphate-buffered saline at a pH of
7.4. AMD3465 was administered daily by intraperitoneal injection
at a dose of 10 mg/kg. LY294002 was obtained from Sigma-Aldrich
(St Louis, MO). Recombinant human stromal cell–derived factor 1α
was obtained from ProSpec-Tany Technogene Ltd (Rehovot, Israel).
Five micrograms of recombinant human SDF-1α was administered
by tail vein injection thrice weekly over a 28-day period.
Pancreas Patient-Derived Explants and Cell Lines
Six-week-old female athymic nude mice (Harlan, Indiana, IN)
were used. The research protocol was approved by the Johns Hopkins
University Animal Care and Use Committee, and animals were main-
tained in accordance to the guidelines of the American Association of
Laboratory Animal Care. Surgical nondiagnostic specimens obtained
by pancreaticoduodenectomy at the Johns Hopkins Hospital were
reimplanted subcutaneously to derive human pancreatic cancer explant
xenografts. Xenografted tumors were allowed to grow until reaching
∼200 mm3, at which time mice were randomized into treatment
groups consisting of control and various experimental groups [27].
Each group contained 8 to 10 tumors that can be evaluated depending
on the experiment. Mice were monitored daily for signs of toxicity and
were weighed three times per week. Tumor size was evaluated two
times per week by caliper measurements using the following formula:
tumor volume = (length × width2) / 2. Relative tumor growth inhibi-
tion was calculated by dividing the tumor volumes of treated mice by
those of control mice (percent growth of treated group/control group
for each individual). The temsirolimus-resistant pancreatic cancer cell
line HS766T was used in in vitro cell signaling experiments.
Real-time Polymerase Chain Reaction
RNA was isolated from cells or tumor samples using standard pro-
cedures of Qiagen RNeasy Mini Kit. Pancreas Xenograft comple-
mentary DNA library synthesis was performed with BioRad iScript
Reaction Kit using 5× iScript Reaction mix, reverse transcriptase,
RNAse-free water, and RNA. Real-time polymerase chain reaction
(PCR) was performed using human c-Fos, CXCR4, CXCR7, cyclin
D1, c-Myc, EGFR, SDF-1α, VEGF, and 18S primer probes (Applied
Biosystems, Foster City, CA) plus TaqMan (Applied Biosystems) in
the iQ5 iCycler real-time PCR detection system (Bio-Rad, Hercules,
CA). 18S amplification was used as the housekeeping gene. Reaction
involved an initial cycle at 50°C for 2 minutes followed by 95°C for
10 minutes. Lastly, 40 cycles at 95°C for 15 seconds and then 60°C
for 1 minute. A gene expression score was calculated by taking 2 raised
to the difference in C t between the housekeeping gene and the gene of
interest (2ΔC t).
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Western Blot Analysis
Cells were lysed in lysis buffer containing 50 mMTris-HCl, pH 7.4,
150 mM NaCl, 0.5% NP-40, phosphatase inhibitors (EDTA-free
protease inhibitors; Boehringer Mannheim, Petersburg, VA), 20 mM
β-glycerol phosphate, 20mMNaF, and 1mMNaVO3. Equal amounts
of protein (60 μg) were separated on 4% to 12% gradient SDS-PAGE
and transferred onto a nitrocellulose membrane at 100 V for 1 hour.
Membranes were blocked with 5% milk in TBST (20 mM Tris-HCl
pH 7.5, 500 mM NaCl, and 0.5% Tween 20) for 1 hour at room
temperature and incubated with appropriate dilutions of primary anti-
bodies (1:1000, Akt [p-Ser473], Akt [p-Thr308], Akt, HIF-1α, and
β-actin; 1:5000, p-S6-RP [Ser235/236], S6-RP) from Cell Signaling
Technology, (Danvers, MA) and CXCR4 and VEGF from Santa
Cruz Biotechnology, Inc (Santa Cruz, CA), in 5% nonfat dried milk
in TBST overnight at 4°C. The membrane was washed five times for
5 minutes with TBST and incubated with a 1:2000 dilution of horse-
radish peroxidase–conjugated goat–anti-rabbit or -mouse secondary
antibody for 1 hour at room temperature. After this, the membrane
was washed again five times for 5 minutes with TBST and developed
using an ECL reagent (VWR International, Radnor, PA).
CXCR4 and CXCR7 Knockdown
HS766T cells were cultured to 80% confluence the day before
transfection. The standard protocol using Lipofectamine by Invitrogen
(Grand Island, NY) was used to transiently transfect the cells with
GIPZ lentiviral short hairpin RNA (shRNA) from Open Biosystems
(Lafayette, CO).We used shCXCR7, shCXCR4, and shGIPZ scramble.
CXCR4 and CXCR7 quantitative real-time PCR was performed to
determine gene transcription repression efficiency of shRNA integration.
Immunohistochemical Staining
Explanted tumor specimens were fixed in 10% buffered formalin
and embedded in paraffin. The sections were subsequently dewaxed
and rehydrated in graded ethanol. Antigen retrieval was performed
by soaking sections in 10 mM sodium citrate buffer (pH 6.0) and heat-
ing in a high-power microwave oven for 20 minutes. The sections were
incubate in primary antibody targeting either anti-human CXCR4
or anti-human VEGF antibody for 30 minutes at room temperature.
After washing, the secondary antibody was added and incubated for
an additional 30 minutes. Reactive products were detected with 3,3′-
diaminobenzidene and counterstainedwith hematoxylin for 30 seconds.
Statistical Analysis
To assess the treatment effect, a hierarchical linear regression model
was used with random intercepts and fixed slopes to evaluate the 2627
individual tumors from 16 individual patient-derived xenografts treated
with temsirolimus versus placebo. On the basis of the results of explor-
atory plots, the assumption of fixed effects for slopes was deemed rea-
sonable. This model allowed for mouse effects to be nested within
patient effects so that the hierarchical structure is fully accounted for.
Specifically, we fit the following linear regression model:
log yijt
 
= a1ijtimeijt + b2jtimeijt × trtij + βtime2ijt + eijt
where j indexes patient, i indexes mouse, and t indexes time, yijt is the
percentage change in tumor volume (compared to day 0) in mouse i,
which is a xenograft for patient j at time t, and trtij is treatment (1 = trea-
ted, 0 = control) received by mouse i which is a xenograft for patient j.
We explored a series of models to determine a good fitting model and
found that the previously mentioned model was adequate. An intercept
and main effect of treatment were not included in the model that makes
two assumptions: 1) at time 0, the change from baseline is zero (which is
empirically true); and 2) at baseline, the treated and untreated curves
intersect. The model was fit using WinBugs software that estimates
models using a Markov chain Monte Carlo estimation procedure. A
burn-in of 10,000 iterations was performed, and then the chain was
run for an additional 20,000 iterations, of which every 10th iteration
was saved for inference. Several chains were run with different starting
values to ensure convergence. No convergence issues arose. The fitted
model was used to make inferences with respect to the treatment effect
and to create fitted regression lines (rescaled on the y axis for clearer
interpretation). Point estimates of parameters of interest (e.g., expected
difference in tumor volume between treated and control at 28 days) and
95%credible intervals and tail probabilities were used for inference based
on themean of posterior distributions and the 2.5th and 97.5th quartiles
of the posterior distribution, respectively.
Pearson correlation was used to determine the correlation of gene
expression with tumor growth. All molecular studies were performed
at least three times with similar results obtained between replicates.
Statistical analysis was performed using Student’s t test. Significant
associations were defined when P < .05 compared with control.
One-way analysis of variance was used to determine treatment effects
of therapy relative to control in patient-derived xenograft experiments.
Turkey multiple comparison test was used to determine significance of
intergroup comparisons.
Results
SDF-1 Gene Expression Is Associated with
Temsirolimus Resistance
Previous work by our group demonstrated that a patient-derived
pancreas explant xenograft model could be used as a platform for
pharmacodynamic-based evaluation of the mTOR inhibitor temsiro-
limus [27]. This analysis used a hierarchical linear regression analysis
to demonstrate that temsirolimus treatment of mice bearing pancreas
patient explant xenografts from individual patients resulted in signif-
icant tumor growth inhibition, P < .00001 (Figure W1). However, a
significant interxenograft variability in temsirolimus tumor growth-
inhibitory effects was observed. As such, mechanisms of resistance
need to be defined. Sensitivity to temsirolimus did not correlate with
intratumoral p70/S6 kinase activity (data not shown).
The chemokine SDF-1α has been demonstrated to activate Akt and
ERK upon binding to its receptor CXCR4 [19]. Therefore, we hypoth-
esized that activation of CXCR4 by SDF-1αmay provide an alternative
stimulatory signal, resulting in mTOR activation to promote resistance
tomTOR-targeted therapy. First, we attempted to link baselineCXCR4
and SDF-1α gene expression with temsirolimus growth-inhibitory
effects. CXCR4 and SDF-1α mRNA expression was assessed by real-
time PCR in baseline tumor specimens before study initiation. Only
SDF-1α gene expression, not CXCR4, demonstrated a statistically
significant correlation with temsirolimus-induced tumor growth inhibi-
tion. Baseline SDF-1α gene expression was inversely related to
temsirolimus-induced growth inhibition (Figure 1A ). Analysis of
SDF-1α gene expression after temsirolimus treatment demonstrated that
temsirolimus-resistant patient-derived xenografts retained SDF-1α
gene expression in comparison to temsirolimus-sensitive patient-derived
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xenografts (Figure 1B ). These observations may reflect the ability of
SDF-1α to bind to either CXCR4 or CXCR7 to propagate signal trans-
duction events.
SDF-1α Stimulation of CXCR4 Directly Regulates mTOR
Pathway Activation
The subsequent experiments were designed to demonstrate that
CXCR4 activation by SDF-1α directly regulates the PI3-kinase/
Akt/mTOR pathway. To achieve this goal, the temsirolimus-resistant
pancreatic cancer cell line HS766T was stimulated with SDF-1α
(100 ng/ml) followed by subsequent PI3-kinase/Akt/mTOR pathway
interrogation by Western blot analysis. SDF-1α stimulation of HS766T
cells resulted in complete Akt activation, signified by the combined
phosphorylation of both threonine 308 (Thr308) and serine 473
(Ser473) Akt residues within 60 minutes (Figure 2A). Similarly, max-
imal mTOR pathway activation, as measured by S6-ribosomal protein
(S6-RP) phosphorylation, in response to SDF-1α stimulation also
occurred at 60 minutes. SDF-1α–induced mTOR pathway activation
was maintained through 8 hours. Although SDF-1α–induced S6-RP
phosphorylation occurs initially within 5 minutes, as a result of Akt
Thr308 phosphorylation, maximal SDF-1α–induced mTOR pathway
activation required phosphorylation of both Thr308 and Ser473 resi-
dues. Persistent S6-RP phosphorylation seemed to be maintained by
the Akt Ser473 residue.
SDF-1α serves as the ligand for two G protein–linked receptors,
CXCR4 and CXCR7, both of which may have a role in pancreatic
cancer tumorigenesis [28]. Cell surface expression analysis of CXCR4
and CXCR7 by FACS demonstrated that 0.29% of HS766T cells
express CXCR4, representing a 10-fold increase over CXCR7
(0.02%). Virtually no cells possessed dual cell surface expression of
CXCR4 and CXCR7 (Figure W2A). RNA interference was used to
demonstrate that CXCR4 is the primary receptor responsible for the
propagation of SDF-1α–mediated regulation of the mTOR pathway
in pancreatic cancer cells. This was accomplished by incubating
SDF-1α–stimulated HS766T cells with either nontarget small inter-
fering RNA (NT-RNAi) or CXCR4 targeting shRNA (CXCR4-RNAi)
for 60 minutes. Knockdown of CXCR4 by CXCR4-RNAi specifically
inhibited SDF-1α–induced Akt phosphorylation at both Thr308 and
Ser473 residues, as well as S6-RP phosphorylation when compared
to nontargeting siRNA (Figure 2B). In contrast, CXCR7-targeted
Figure 1. (A) Pearson correlation was used to define the relationship between baseline SDF-1α mRNA expression in the patient-derived
pancreas explant xenografts normalized to the lowest expresser to the individual patient-derived pancreas explant xenograft in response
to temsirolimus, R = 0.586, P = .01. (B) SDF-1α mRNA expression at baseline and after temsirolimus treatment of both temsirolimus-
resistant and -sensitive pancreas explants.
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RNA interference assays failed to demonstrate alterations in SDF-1α–
mediatedmTOR pathway activation (FigureW2, B andC ). These data
define CXCR4 as the primary receptor used by SDF-1α to regulate
mTOR pathway activation.
The role of PI3-kinase in SDF-1α–CXCR4-mediated mTOR
pathway activation was demonstrated by exposing HS766T cells to
SDF-1α in the presence of the PI3-kinase inhibitor LY294002.
HS766T cells were stimulated with SDF-1α for 60 minutes with
increasing concentrations of LY294002 ranging from 0.5 to 10 μM.
LY294002 exposure inhibited SDF-1α–induced Akt and S6-RP phos-
phorylation in a concentration-dependent manner (Figure 2C ). Micro-
molar LY294002 concentrations inhibited Akt phosphorylation at
both Thr308 and Ser473, which was associated with near-total inhibi-
tion of S6-RP phosphorylation. In contrast, LY294002 concentrations
Figure 2. SDF-1α activation of CXCR4 regulates mTOR pathway activation. The pancreatic cancer cell line HS766T was stimulated with
SDF-1α (100 ng/ml) and interrogated for evidence of mTOR pathway activation by Western blot analysis of total CXCR4, total Akt, Akt
phosphothreonine 308 (p-AKT [THR308]), Akt phosphoserine 473 (p-AKT [SER473]), total S6 ribosomal protein (t-S6-RP), phosphorylated
S6 ribosomal protein (p-S6-RP) as indicated in the individual panels. β-Actin serves as the protein loading control. (A) HS766T cells were
serum starved for 18 hours and then stimulated with SDF-1α for 24 hours to demonstrate kinetics of mTOR activation stimulated by
SDF-1α exposure. Images are representative experiments performed three times. (B) Cells were exposed to SDF-1α for 60 minutes in the
presence of nontargeting shRNA (NT-RNAi) and CXCR4-targeted shRNA (CXCR4-RNAi). (C) Cells were exposed to SDF-1α for 60 minutes
in the presence of the PI3-kinase inhibitor LY294002 at the designated concentrations. (D) Cells were exposed to SDF-1α for 60 minutes
and temsirolimus. Lane 3 demonstrates exposure to temsirolimus for 30 minutes before SDF-1α stimulation. In lanes 4 to 7, HS766T
cells were exposed to SDF-1α for a period of 60 minutes. Temsirolimus (20 nM) was added for incubation at specified times within the
60-minute incubation period.
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of 1 μM or less inhibited Akt phosphorylation only at the Thr308
residue and were unable to prevent SDF-1α–induced S6-RP phosphor-
ylation. These finding substantiate the importance of dual phosphory-
lation of Akt at residues Thr308 and Ser473 to result in maximal
mTOR pathway activation by SDF-1α/CXCR4 (Figure 2A).
The ability of SDF-1α–CXCR4 to serve as a compensatory signal
transduction pathway to promote temsirolimus resistance by main-
taining fidelity of the mTOR pathway activation was investigated.
First, SDF-1α (100 ng/ml) induced Akt and S6-RP phosphorylation
in HS766T cells after stimulation for 60 minutes as predicted (lanes 1
and 2 of Figure 2D). Next, HS766T cells were treated with tem-
sirolimus either before or after SDF-1α stimulation to define the abil-
ity of SDF-1α to maintain mTOR pathway activation relative to the
timing of temsirolimus exposure in an attempt to mimic physiologic
conditions associated with in vivo temsirolimus treatment. HS766T
cells were pretreated with temsirolimus (20 nM) for 30 minutes before
SDF-1α stimulation (lane 3 of Figure 2D). Temsirolimus pretreatment
inhibited SDF-1α–induced S6-RP phosphorylation but promoted Akt
Ser473 phosphorylation without altering Thr308 phosphorylation.
Next, the ability of antecedent SDF-1α–CXCR4 to maintain mTOR
pathway fidelity in association with temsirolimus exposure was anal-
yzed. To accomplish this, HS766T cells were stimulated with SDF-1α
(100 ng/ml) for 60 minutes and temsirolimus was added either simul-
taneously or at 15-minute intervals (after 0, 15, 30, and 45 minutes)
throughout the SDF-1α incubation period (lanes 4 to 7 of Figure 2D).
Simultaneous exposure to SDF-1α and temsirolimus inhibited S6-RP
phosphorylation (0 minute; lane 4 of Figure 2D). In contrast, SDF-1α
stimulation before temsirolimus exposure promoted S6-RP phosphory-
lation in a time-dependent manner (after 15, 30, and 45 minutes). The
ability of SDF-1α to maintain S6-RP phosphorylation was associated
with the incremental inhibition of Ser473 phosphorylation. Together,
these data demonstrate that SDF-1α–induced CXCR4 activation pro-
vides a secondary signal to propagate PI3-kinase/Akt–dependent mTOR
pathway activation that can overcome temsirolimus-induced mTOR
pathway inhibition. Furthermore, these data provide evidence that a
microenvironmental factor present within the tumor milieu can directly
promote resistance to mTOR-targeted therapy despite adequate tumor
cell exposure.
Figure 3. Temsirolimus-resistant xenograft Panc159 treated with temsirolimus and AMD3465. (A) Growth curve of Panc159 xenograft
treated with temsirolimus and AMD3465: control (♦), AMD3465 ( ), temsirolimus ( ), or the combination of temsirolimus and
AMD3465 ( ) for 28 days. Growth curves represent percent growth of treated tumors throughout the study treatment. The experiments
were conducted with 10 tumors per treatment group, and error bars represent ±SEM. (B) Intratumoral cyclin D1 mRNA expression.
(C) Intratumoral c-myc mRNA expression. Presented data for B and C are from three individual tumors per group replicated three times,
and error bars represent ±SEM. *P < .05, **P < .01.
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Pharmacodynamic Analysis of CXCR4-Mediated
Temsirolimus Resistance
A pharmacodynamic approach was used to directly test the ability
of the SDF-1α–CXCR4 ligand-receptor pair to mediate temsirolimus
resistance. First, we reasoned that CXCR4 inhibition should over-
come resistance to temsirolimus as defined by previous observations
that tumor growth inhibition of 40% or greater in xenografts pre-
dicts clinical resistance. Combined treatment with temsirolimus
and the CXCR4 inhibitor, AMD3465 of the temsirolimus-resistant
human pancreatic cancer explant xenograft Panc159 resulted in syn-
ergistic growth inhibition in comparison to treatment with either
drug alone (Figure 3A ). CXCR4 inhibition by AMD3465 was not
associated with significant intratumoral pS6-RP reduction compared to
temsirolimus-treated tumors (data not shown). Decreased expressions
of cyclin D1 and c-myc serve as measurements of 4E-BP1 function and
have previously been demonstrated to promote the growth-inhibitory
effects of rapalogs [29].Dual CXCR4 andmTOR inhibitionmodulated
4E-BP1 function by synergistically inhibiting temsirolimus-induced
intratumoral cyclin D1 and c-myc gene expression (Figure 3, B and C ).
Next, we confirmed that both the ligand and the receptor are necessary
in vivo for SDF-1α–CXCR4 ligand-receptor pair-mediated mTOR-
targeted therapy resistance. The CXCR4+/SDF-1α− temsirolimus-
sensitive human pancreatic cancer explant xenograft Panc410
(Figure W3B) was exposed to exogenous human SDF-1α by tail vein
injection to demonstrate that SDF-1α–mediated CXCR4 activation
induces a temsirolimus-resistant phenotype. The injection of SDF-1α
resulted in moderate increased tumor growth relative to treatment with
temsirolimus alone (Figure 4A). Concomitant treatment with SDF-1α
and AMD3465 nullified SDF-1α–augmented tumor growth in the
presence of temsirolimus. Furthermore, SDF-1α exposure specifically
induced both cyclin D1 and c-myc gene expression that was inhibited
by AMD3465 treatment (Figure 4B ). In combination, the Panc159
and Panc410 xenograft experiments provide evidence that the SDF-1α/
CXCR4 ligand-receptor pair specifically mediate resistance to temsiro-
limus therapy in vivo.
EGFR Partners with CXCR4 to Induce mTOR-Targeted
Therapy Resistance
Epidermal growth factor receptor (EGFR) is a primary receptor
involved in microenvironmental regulation of pancreatic cancer cell
function. As such, targeting EGFR with erlotinib is a clinically used
strategy for the treatment of patients with pancreatic cancer [30]. c-Fos
expression has previously been demonstrated to correlate with erlotinib
growth-inhibitory effects in in vivo preclinical pancreatic cancer models
Figure 4. SDF-1α exposure specifically induces resistance to temsirolimus. (A) Temsirolimus-sensitive patient-derived pancreas xeno-
graft Panc410 (CXCR4+/SDF-1α−) was treated with either temsirolimus (♦), temsirolimus and SDF-1α ( ), or temsirolimus plus SDF-1α
and AMD3465 ( ) for 28 days. Growth curves represent percent tumor growth of treated tumors relative to control (temsirolimus):
temsirolimus plus SDF-1α, temsirolimus plus SDF-1α, and AMD3465. The experiments were conducted with eight tumors per treatment
group, and error bars represent ±SEM. (B) Intratumoral gene expression for human cyclin D1 and c-myc mRNA expression. Presented
data are from three individual tumors per group replicated three times, and error bars represent ±SEM. *P < .05, **P < .01.
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[31]. Treatment of the temsirolimus-resistant Panc159 xenograft with
AMD3465 resulted in the attenuation of both c-fos and EGFR gene
expression (Figure 5, A and C ). Induction of a temsirolimus-resistant
phenotype by SDF-1α in the temsirolimus-sensitive explant Panc410
resulted in a two-fold induction of intratumoral c-fos gene expression
(Figure 5B ). Combined, these data provide evidence that SDF-1α–
CXCR4–mediated signal transduction may directly regulate EGFR
expression to promote mTOR-targeted therapy resistance. Based on
these observations, we hypothesized that EGFR-targeted therapy would
augment the ability of AMD3465 to overcome temsirolimus resistance.
As hypothesized, treatment of the ultimate temsirolimus-resistant
human pancreas explant Panc194 with the combination of AMD3465
and erlotinib resulted in significant tumor regression when combined
with temsirolimus, thereby overcoming temsirolimus resistance (Fig-
ures W3C and 5D). The effect of combining AMD3465 and erlotinib
with temsirolimus on tumor growth inhibition seems additive to the
effects of combining AMD3465 or erlotinib with temsirolimus. The
impact of the combination of AMD3465, erlotinib, and temsirolimus
on tumor growth was also demonstrated by total growth inhibition in
some tumors within the cohort, resulting in near-total growth inhibi-
tion in comparison to control by day 21, which was not obtained in
the other treatment groups (Figure W4). Combined, these data demon-
strate that secondary signals propagated by the interaction of physiologic
stromal components with cancer cell surface receptors possess the ability
to directly initiate temsirolimus resistance in part by maintaining the
fidelity of the PI3-kinase/Akt/mTOR pathway. The hypoxic nature of
pancreatic cancer makes these observations particularly important because
hypoxia promotes the transcription of SDF-1α, CXCR4, and EGFR.
CXCR4 Regulates VEGF Expression
Pancreatic cancer cells use hypoxia-inducible proteins to adapt to
the hypoxic microenvironment in which they grow. CXCR4, SDF-1α,
and VEGF gene expression are all regulated by hypoxia. In this context,
SDF-1α–CXCR4 signaling directly regulates VEGF transcription [32].
Initial evaluation of baseline VEGF gene expression did not demon-
strate a relationship between baseline VEGF gene expression and
temsirolimus growth inhibition (data not shown). However, baseline
SDF-1α− gene expression was directly associated with that of VEGF.
Figure 5. CXCR4 inhibition implicates EGFR as a potential partner with CXCR4 for the induction of temsirolimus resistance. (A) Intra-
tumoral c-fosmRNAexpressionobtained from thePanc159xenograft treatedwithAMD3465 and temsirolimus. (B) Panc410 intratumoral c-fos
mRNA expression treatedwith temsirolimus and exposed to exogenous human SDF-1α and AMD3465. (C) Intratumoral EGFRmRNA expres-
sion obtained from the Panc159 xenograft treated with AMD3465 and temsirolimus. Presented data for A, B, and C are from three individual
tumors per group replicated three times, and error bars represent ±SEM. *P < .05, **P < .01. (D) Growth curve of temsirolimus-resistant
Panc194 xenograft treated with temsirolimus, AMD3465, and erlotinib: control (♦), AMD3465 ( ), temsirolimus ( ), temsirolimus and
AMD3465 ( ), temsirolimus and erlotinib (□), erlotinib and AMD3465 (○), or temsirolimus, AMD3465 and erlotinib () for a period of 28 days.
Growth curves represent percent growth throughout the study drug exposure period. The experiments were conducted with 10 tumors per
treatment group, and error bars represent ±SEM. *P < .01.
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Tumors from temsirolimus-resistant xenografts demonstrated in an
increased frequency of VEGF expressing tumors in six (86%) of seven
in contrast to four (44%) of nine temsirolimus-sensitive xenografts
(Figure 6A). In addition, VEGF-containing temsirolimus-resistant
xenografts possessed increased levels of VEGF in comparison to their
counterpart temsirolimus-sensitive xenografts. Temsirolimus-resistant
tumors also tended to maintain VEGF expression after temsirolimus
exposure (Figure W5A). The importance of this observation is that
VEGF protein expression has been associated with mTORC1 inhibitor
resistance and may serve as a marker of persistent PI3-kinase/Akt/
mTOR pathway activation. Consistent with the hypothesis of interplay
between SDF-1α–CXCR4 signaling and VEGF, both VEGF and
CXCR4 were expressed in pancreas tumor cells at the leading edge of
the explanted tumor (Figure W5, C and D). The direct relationship
between SDF-1α–CXCR4 signaling and VEGF expression was evalu-
ated in subsequent experiments.
The regulation of angiogenesis by mTOR through its effects on
VEGF production is an important adaptive process used by cancer
cells to survive hypoxic conditions. SDF-1α–CXCR4 ligand-receptor
pair signaling promotes angiogenesis by a number of mechanisms
including the direct promotion of VEGF transcription [32]. The
relationship between SDF-1α–CXCR4 signaling, and VEGF expres-
sion was evaluated using the pharmacodynamic approach. As such,
intratumoral VEGF mRNA and protein expression in tumors ob-
tained from the aforementioned pharmacodynamic experiments were
evaluated. AMD3465 treatment of the temsirolimus-resistant xeno-
graft Panc159 inhibited intratumoral VEGF gene and protein ex-
pression (Figure 6, B and D). In contrast, SDF-1α exposure of the
temsirolimus-sensitive xenograft Panc410 increased intratumoral
VEGF gene and protein expression, which was specifically inhibited
by AMD3465 (Figure 6, C and E ). The pancreatic cancer cell line
HS766T was used to demonstrate the direct ability of SDF-1α to
regulate VEGF transcription in pancreatic cancer cells. SDF-1α
(100 ng/ml) stimulation of HS766T cells resulted in an eight-fold
increase in VEGF expression occurring at 4 hours, thus demonstrat-
ing the direct effects of SDF-1α–CXCR4 on VEGF transcription
(Figure W5B ). These data provide evidence that CXCR4 regulates
VEGF intratumoral production by pancreatic cancer cells in an
mTOR-dependent manner.
Discussion
Pancreatic cancer remains a devastating disease with limited thera-
peutic options. Gemcitabine combined with either capecitabine or
erlotinib remains the standard of care and provides marginal impact
on patient survival [30,33–35]. The early acquisition of activating
mutations of K-ras in pancreatic adenocarcinoma oncogenesis places
Figure 6. Intratumoral VEGF expression is inhibited by pharmacologic inhibition of CXCR4. (A) Western blot of basal protein expression
in explant probed for CXCR4 and VEGF. (B) Intratumoral VEGF mRNA expression obtained from the Panc159 xenograft treated with
AMD3465 and temsirolimus. (C) Panc410 intratumoral VEGF mRNA expression in xenografts treated with temsirolimus and exposed
to exogenous human SDF-1α and AMD3465. Presented data for B and C are from three individual tumors per group replicated three
times, and error bars represent ±SEM. **P < .01. (D) VEGF protein expression from Panc159-xenografted tumors treated with temsir-
olimus and AMD3465. (E) Panc410 VEGF protein expression in xenografts treated with temsirolimus and exposed to exogenous human
SDF-1α and AMD3465. Protein lysates were immunoblotted with antibodies recognizing VEGF protein. β-Actin serves as the protein
loading control. Presented data are from a mean of three individual replicate experiments, and error bars represent ±SEM. ***P < .001.
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mTOR as a central node in the initiation and maintenance of pan-
creatic adenocarcinoma oncogenesis [3]. A fundamental set of 12 sig-
naling pathways has been demonstrated to undergo genetic alteration
during pancreatic cancer oncogenesis [36]. Interestingly, many of these
pathways interact with mTOR. These observations, combined with
preclinical testing of mTOR inhibitors, support the development of
this class of compound for pancreatic cancer therapy. However, recent
clinical trials have failed to demonstrate the degree of clinical efficacy
as would be predicted by the available preclinical models [13–15]. The
inability to translate preclinical observations of tumor growth inhi-
bition by mTOR inhibitors into clinical benefit for patients with pan-
creatic cancer may be explained by the utilization of inappropriate
thresholds to define sensitivity in preclinical models [15]. Alternatively,
undetermined secondary signals provided by the tumor micro-
environment or intratumoral genetic alterations may be able to directly
overcome mTOR inhibition. In this study, we demonstrate that acti-
vation of the G-protein-linked receptor CXCR4 by the chemokine
SDF-1α (CXCL-12) mediates resistance to mTOR-targeted therapy in
pancreatic cancer.
The results of this study demonstrate two disparate but related
mechanisms by which CXCR4 activation can mediate resistance to
mTOR-targeted therapy. The role of SDF-1α–CXCR4 signaling in
pancreatic cancer biology is becoming increasingly apparent, partic-
ularly because it promotes the metastasis of pancreatic cancer stem
cells. As such, SDF-1α binding to its receptor CXCR4 may represent
a mechanism by which the tumor cell microenvironment may regu-
late intracellular events to promote resistance to signal transduction
pathway inhibitors. As such, CXCR4 possesses the ability to directly
regulate the activation state of the mTOR pathway in a PI3-kinase–
dependent manner. Specifically, stimulation of SDF-1α–CXCR4 sig-
naling before temsirolimus exposure maintained the fidelity of mTOR
signal transduction despite pharmacologic inhibition by temsirolimus.
In contrast, SDF-1α–CXCR4 stimulation failed to mediate these effects
in the context of prior temsirolimus exposure. This is a significant find-
ing in that the hypoxic nature of pancreatic cancer would likely result
in a basal level of intratumoral SDF-1α production, thereby initiating
SDF-1α–CXCR4 signaling to promote mTOR pathway activation.
As demonstrated by the aforementioned experiments, basal intra-
tumoral SDF-1α production would be predicted to result in inherent
resistance to mTOR-targeted therapy in patients. If true, this observa-
tion may provide insight into the lack of clinical efficacy of mTOR
inhibitor in the treatment of patients with pancreas adenocarcinoma.
The CXCR4 receptor likely represents a minority of receptors
expressed on pancreatic cancer cells. One might hypothesize that recep-
tors such as EGFR, which possess receptor tyrosine kinase function,
may be a more significant regulator of the mTOR pathway by extra-
cellular signals. In this case, SDF-1α–CXCR4 may serve to amplify
EGFR-mediated signal transduction. Interactions between SDF-1α
and EGFR have previously been demonstrated in that SDF-1α pro-
motes EGFR phosphorylation and gene expression in ovarian cancer
cells [37]. In addition, EGFR expression combined with hypoxia-
induced CXCR4 expression in primary non–small cell lung cancer cells
has been demonstrated to promote metastasis [38]. Here we demon-
strate that SDF-1α promotes both c-Fos and EGFR transcription in
pancreatic cancer. c-Fos expression has previously been demonstrated
to correlate with the antiproliferative effects of EGFR pathway inhibi-
tion in pancreatic cancer [31]. The functional relevance of SDF-1α–
mediated EGFR regulation in pancreas was demonstrated by the ability
of dual EGFR and CXCR4 inhibition combined with temsirolimus to
overcome temsirolimus resistance in the human explant xenograft
model. This observation is akin to the interplay of insulin-like growth
factor receptor 1 and c-Met signal transduction and resistance to
EGFR-targeted therapy in non–small cell lung cancer [39,40]. These
data support the hypothesis that strategies incorporating mTOR-based
therapy in pancreatic cancer may be effective but will require the use of
vertical signal transduction inhibitory strategies. Such strategies should
use proximal receptor kinase inhibition in conjunction with the nodal
mTOR inhibition. This strategy may have the capacity to overcome the
lack of oncogenic addition displayed in pancreatic cancer resulting from
the multiple genetic pathways involved in pancreatic oncogenesis [36].
In addition, these results may be of significant clinical relevance because
it provides evidence for a combinatorial molecular strategy to augment
EGFR-targeted therapy in pancreatic cancer [35]. Taken together,
these data identify SDF-1α–CXCR4–mediated signal transduction as
a tumor microenvironment-regulated process that possesses the capac-
ity to directly mediate mTOR-targeted therapy resistance.
Modulation of VEGF expression represents the second mechanism
by which SDF-1α–CXCR4 may promote mTOR-targeted therapy
resistance. The linkage of VEGF production with CXCR4-regulated
resistance to mTOR-targeted therapy implies that CXCR4 may be
used by the pancreatic cancer cells to promote angiogenesis. In this
context, CXCR4 regulation of Yin Yang 1 promotes VEGF transcrip-
tion to promote angiogenesis during malignancy [32]. The finding that
SDF-1α stimulation promotes VEGF transcription supports the ability
of pancreatic cancer cells to directly regulate angiogenesis. The impor-
tance of angiogenesis in pancreatic cancer has recently been reevaluated
in the context of sonic hedgehog pathway inhibition leading to altered
angiogenesis in association with pronounced growth-inhibitory effects
when combined with gemcitabine [41]. In this context, sonic hedgehog
pathway inhibition results in the modulation of the pancreatic cancer
stromal architecture allowing for increased vascular patency. Vascular
patency is compromised as a function of the increased interstitial pressure
exerted by the tumor-stromal components. The increased vascular pa-
tency in turn allows for increased transit of chemotherapeutic agents
of a variety of sizes resulting in an increase in intratumoral pharmaco-
kinetic parameters of the chemotherapeutic agent. This observation
may explain some perplexing clinical findings such as the lack of clinical
efficacy associated with EGFR-targeted antibodies, in contrast to that
observed with the small-molecule inhibitor erlotinib [35,42]. Similarly,
this observationmay be key to the lack of bevacizumab efficacy in clinical
evaluation when compared to preclinical analysis [43]. Furthermore,
targeting angiogenesis by either antibodies or small-molecule inhibitors
may have no therapeutic effect without altering the stroma architecture.
Interestingly, preclinical models of sonic hedgehog and mTOR pathway
inhibition demonstrate additive growth-inhibitory effects [44].
In terms of the angiogenesis and the tumor-stromal compartment,
SDF-1α–CXCR4–mediated signal transduction may have multiple
roles. Both bone marrow–derived endothelial cell precursors and
cancer-associated fibroblasts have been demonstrated to migrate to
cancer foci in a SDF-1α–CXCR4–dependent manner. Both of these
events may occur in response to hypoxia. The regulation of endothe-
lial cell precursors along with cancer-associated fibroblast may be not
only important for conditioning of the nascent pancreatic cancer
microenvironment but also critical for conditioning of the metastatic
niche [45,46]. Conditioning of the metastatic microenvironmental
niche to promote angiogenesis may facilitate the survival of the met-
astatic cell by allowing it to overcome the relative hypoxia associated
with a new microenvironment [45]. The cancer-associated fibroblast
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cell population may ultimately give rise to liver stellate cells. Liver
stellate cells have been demonstrated to function as nurse cells to sup-
port metastatic cancer cells within the liver in an SDF-1/CXCR4–
dependent manner [47]. In addition to its role in the regulation of
homing of potential stromal components, CXCR4 has been demon-
strated to mediate the metastasis of pancreatic cancer stem cells to
the liver [48]. Thereby, CXCR4 may have multiple functions in pan-
creatic cancer biology including direct effects on various subtypes of
pancreatic cancer cells in addition to its effects on various stromal com-
ponents, all of which may be regulated in part by VEGF in response to
tumor-associated hypoxia.
In conclusion, we demonstrate that basal SDF-1α gene expression
does not simply serve as a biomarker mTOR-targeted therapy resis-
tance but functionally regulates the mTOR pathway to promote
mTOR-targeted therapy resistance. Furthermore, SDF-1α–CXCR4
recruits EGFR to presumably further amplify mTOR pathway acti-
vation to promote mTOR-targeted therapy resistance. The combina-
tion of mTOR-targeted therapy with that of EGFR and CXCR4 may
represent a novel therapeutic strategy to augment EGFR-targeted
therapy in pancreatic cancer. Functional analysis of mTOR pathway
activation demonstrated that VEGF signaling is regulated by SDF-1α–
CXCR4, thereby providing implications for a role of angiogenesis in
this process.
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Figure W1. Growth-inhibitory effects of temsirolimus in pancreas xenografts. Treatment of patient-derived pancreas xenograft in nude
mice treated with temsirolimus. Hierarchical linear regression model–fitted growth curves to the individual tumor volume measurements
for 16 patient-derived pancreas xenografts treated with temsirolimus ( ) versus placebo controls (•) demonstrate temsirolimus growth-
inhibitory effects (P < .00001).
Figure W2. (A) FACS analysis of cell surface expression of CXCR4 and CXCR7 on HS766T cells. (B) mRNA expression of parental
HS766T cells, with nontargeting shRNA (NT-RNAi) or CXCR7 shRNA (CXCR7-RNAi). (C) Western blot analysis of total S6 ribosomal protein
(t-S6-RP) and phosphorylated S6 ribosomal protein (p-S6-RP) as indicated in the individual panels in response to SDF-1α stimulation for
60 minutes in CXCR7 knockdown cells.
Figure W3. (A) Table of 16 human pancreas explant xenografts treated with temsirolimus. Growth-inhibitory effect of temsirolimus on
pancreas xenografts represented as percent growth of temsirolimus-treated xenografts ( ) relative to placebo control ( ). (B) Growth
curve of Panc410 treated with temsirolimus versus placebo control representing a temsirolimus-sensitive pancreas xenograft. (C) Growth
curve of Panc194 treated with temsirolimus versus placebo control representing the ultimate temsirolimus-resistant pancreas xenograft.
Growth curves represent tumor volume measurement obtained throughout the study drug exposure period. The experiments were con-
ducted with 10 tumors per treatment group, and error bars represent ±SEM.
Figure W4. Panc194 xenograft tumor growth kinetics analyzed as percent of control volume per day of treatment. Shown are growth
curves of Panc159 xenografts treated with temsirolimus and AMD3465: temsirolimus ( ), AMD3465 ( ), erlotinib and temsirolimus ( ),
AMD3465 and temsirolimus ( ), erlotinib and AMD3465 ( ), and erlotinib, temsirolimus, and AMD3465 (•) for 28 days. Growth curves
represent percent growth of treated tumors throughout study treatment. The experiments were conducted with 10 tumors per treat-
ment group, and error bars represent ±SEM.
Figure W5. (A) Intratumoral protein expression in a temsirolimus-sensitive pancreas explant Panc354 and temsirolimus-resistant pan-
creas explant Panc194 at baseline (Pre) and after temsirolimus treatment (Post). (B) SDF-1α induced VEGF mRNA expression in HS766T
cells. Immunohistochemistry analysis of baseline CXCR4 (C) and VEGF-A (D) protein expression in the Panc410 xenograft.
